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Purpose of review
The epidermal growth factor receptor is a cell membrane
receptor that plays a key role in cancer development and
progression. Ligand-activated epidermal growth factor
receptor-dependent signaling is involved in cell proliferation,
apoptosis, angiogenesis, invasion, and metastasis. Targeting
the epidermal growth factor receptor represents a promising
molecular approach in cancer treatment. Several antiepidermal
growth factor receptor agents are in clinical development. This
review focuses on the available clinical data on epidermal
growth factor receptor-targeting drugs in the treatment of
nonsmall cell lung cancer.
Recent findings
Three drugs are currently in phase 2 and phase 3 development
as single agents or in combination with other anticancer
therapies in nonsmall cell lung cancer patients: cetuximab
(Erbitux), a chimeric human–mouse monoclonal IgG1 antibody
that blocks ligand binding and functional epidermal growth
factor receptor activation; and erlotinib (Tarceva) and gefitinib
(Iressa), two orally bioavailable, small-molecule epidermal
growth factor receptor inhibitors of tyrosine kinase enzymatic
activity that prevent epidermal growth factor receptor
autophosphorylation and activation. Single-agent gefitinib
treatment has determined a 10 to 20% response rate and a 30
to 50% symptom improvement in previously treated,
chemotherapy-refractory advanced nonsmall cell lung cancer
patients. Gefitinib has been the first epidermal growth factor
receptor-targeting agent to be registered as an anticancer
drug in several countries, including Japan, Australia, and the
United States, for the third-line treatment of chemoresistant
nonsmall cell lung cancer patients.
Summary
Antiepidermal growth factor receptor has shown promising
antitumor activity in nonsmall cell lung cancer patients with a
mild toxicity profile. However, a series of important clinical
issues such as selection of potentially responsive patients and
optimal combination with conventional anticancer treatments
needs to be addressed to use these drugs better in lung
cancer.
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Introduction
Epidermal growth factor (EGF) belongs to a family of
related peptides (EGF-like growth factors) that includes
transforming growth factor-, amphiregulin, heparin-
binding EGF, epiregulin, heregulins, neuregulins (1, 2,
3, and 4), and betacellulin [1]. EGF-like growth factors
bind to and activate one or more closely related recep-
tors: the EGF receptor (EGFR, or ErbB-1/HER1),
ErbB-2/neu/HER2, ErbB-3/HER3, and ErbB-4/HER4
[1,2]. The EGFR is a 170-kDa transmembrane glycopro-
tein that consists of an extracellular domain, a short trans-
membrane domain, and an intracellular region contain-
ing tyrosine kinase activity. The other three family
members have a similar structure with a high degree of
homology in the tyrosine kinase domain. The extracel-
lular domains confer different specificity and selectivity
to different EGF-like growth factors and are less con-
served among the four receptors. No ligand is known for
ErbB-2. Receptors exist as inactive monomers [1,2].
Ligand binding causes homodimerization or hetero-
dimerization between the EGFR and another member of
the EGFR family, and subsequent autophosphorylation
of the intracellular domains, which initiates a cascade
of intracellular signals that directly or indirectly control
cell proliferation, angiogenesis, invasion, and metas-
tasis [2,3].
Activation of the transforming growth factor-–EGFR
autocrine growth pathway is a common mechanism for
autonomous nonsmall cell lung cancer (NSCLC) growth
[4]. This is generally the result of EGFR overexpression
without gene amplification and/or the result of increased
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concentration of ligands, such as transforming growth
factor- and amphiregulin [4]. EGFR gene amplification
is observed only in approximately 10% of NSCLCs [5].
Enhanced EGFR expression is observed in 40 to 80% of
NSCLC patients [5,6]. This is accompanied by the ex-
pression of one or more other EGFR family members
and of different ligands with a high degree of heteroge-
neity in both positivity and the levels of expression of
these proteins [6]. Although some reports have sug-
gested a correlation between EGFR overexpression and
worse survival [7], there is no definitive evidence of
a prognostic role of EGFR family members in
NSCLC [4–6].
Epidermal growth factor receptor as a
target for cancer therapy
Two types of anti-EGFR-targeting agents have reached
advanced clinical development: monoclonal antibodies
(MAbs) and small-molecule inhibitors of EGFR tyrosine
kinase enzymatic activity (Table 1) [8,9••,10••]. MAbs
against the extracellular domain of the EGFR block li-
gand binding and receptor activation. Tyrosine kinase
inhibitors (TKIs) prevent the autophosphorylation of the
EGFR intracellular tyrosine kinase domain. These mol-
ecules are generally competitors of ATP for binding to
the intracellular catalytic domain. Although MAbs are
highly specific for EGFR binding, TKIs may be less
selective and may block other members of the EGFR
family. In fact, based on the mechanism of action, small-
molecule EGFR TKIs can be distinguished as reversible
or irreversible TKIs and as selective for the EGFR
or active also against other members of the family
(Table 1).
Although the mechanism of action and the biologic ef-
fects of MAbs and small-molecule TKIs have differ-
ences, such as route of administration and biodistribu-
tion, induction of EGFR downregulation, potential
activation of immune functions that could be clinically
relevant [11•,12•], the antitumor effects of EGFR inhi-
bition in human cancer models are (1) inhibition of can-
cer cell proliferation with G0–G1 cell cycle arrest and, in
some cases, induction of apoptosis; (2) antiangiogenesis
through inhibition of angiogenic growth factor produc-
tion; (3) inhibition of invasion and metastasis; and (4)
potentiation of antitumor activity of cytotoxic drugs and
of radiotherapy [8,9••,10••].
Clinical studies with epidermal growth
factor receptor inhibitors in nonsmall cell
lung cancer
Cetuximab (Erbitux), a chimeric human–mouse anti-
EGFR MAb, and erlotinib (Tarcev) and gefitinib
(Iressa), two orally available, reversible, and selective
EGFR-TKIs, are the most advanced EGFR-targeted
drugs in NSCLC treatment and are discussed in detail in
this review.
Gefitinib
Gefitinib is a low-molecular weight (447 Da), synthetic
anilinoquinazoline derivative. Gefitinib is an orally ac-
tive, selective, and reversible inhibitor of EGFR tyrosine
kinase [13–15]. The initial five phase 1 trials of gefitinib
monotherapy that were conducted in approximately 250
heavily pretreated advanced cancer patients have shown
in 99 NSCLC patients a promising antitumor activity,
with partial responses lasting from 1 to 16 months in
eight patients and regression of nonmeasurable but
evaluable disease in two patients [16••,17••,18,19]. In
addition, approximately one third of patients have had
long-lasting stable disease for 3 months or more. Inter-
estingly, in those patients with tumor response and dis-
ease stabilization, a significant improvement in quality of
life and disease-related symptoms as measured by the
Lung Cancer Subscale of the Functional Assessment of
Cancer Therapy questionnaires was observed [20•]. Ge-
fitinib monotherapy was well tolerated. The most fre-
quently reported adverse events were diarrhea and ac-
nelike skin rash. These side effects were reversible.
Grade 3 diarrhea was dose limiting at the 700- to 1000-
mg dose level. Based on these results, two large phase 2
trials of gefitinib monotherapy in advanced NSCLC pa-
Table 1. Antiepidermal growth factor receptor agents in clinical development
Drug
Biochemical
characteristics
Target
selectivity
Clinical development
in NSCLC
Cetuximab (Erbitux) Human–mouse chimeric MAb Selective for EGFR Phase III
EMD 72000 Humanized MAb Selective for EGFR Phase I
ABX-EGF Fully human MAb Selective for EGFR Phase I
hR3 Humanized MAb Selective for EGFR Phase I
Gefitinib (Iressa) Reversible TKI Selective for EGFR Phase III; as of November 2003,
registered in 10 countries worldwide,
including the United States, as
third-line therapy in NSCLC
Erlotinib (Tarceva) Reversible TKI Selective for EGFR Phase III
CI-1033 Irreversible TKI Pan-ErbB inhibitor Phase I
PKI-166 Reversible TKI EGFR/ErbB-2 dual inhibitor Phase I
GW2016 Reversible TKI EGFR/ErbB-2 dual inhibitor Phase I
EKB-569 Irreversible TKI EGFR/ErbB-2 dual inhibitor Phase I
EGFR, epidermal growth factor receptor; MAb, monoclonal antibody; NSCLC, nonsmall cell lung cancer; TKI, tyrosine kinase inhibitor.
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tients that have failed one or more chemotherapy lines
have been conducted. In a multicenter, European and
Japanese randomized, phase 2 trial of gefitinib as second-
or third-line single-agent therapy (IDEAL 1, or Iressa
Dose Evaluation in Advanced Lung Cancer), 210 ad-
vanced NSCLC patients who were not selected based on
EGFR expression received either 250 mg or 500 mg oral
daily treatment [21••]. An overall response rate of 18.4%
and 19% was observed in the 250-mg and 500-mg gefi-
tinib groups respectively. Stable disease was obtained in
36% and 32% patients respectively. Symptom improve-
ment rates were 40.3% and 37%, median progression-
free survival times were 2.7 months and 2.8 months, and
median overall survival times were 7.6 months and 8.0
months respectively. Gefitinib at the 250-mg daily dose
was equally active compared with 500 mg. However, the
tolerability was significantly better with the 250-mg daily
dose. A parallel phase 2, randomized study was con-
ducted in the United States (IDEAL 2) in 216 unse-
lected, symptomatic, advanced NSCLC patients who
were resistant to at least two previous chemotherapy
regimens, one containing a platinum derivative and one
containing docetaxel [22••]. NSCLC symptoms, as mea-
sured by a 2-point or greater increase in the Functional
Assessment of Cancer Therapy–Lung Cancer Subscale
score, improved in 43% of patients receiving 250 mg
gefitinib and in 35% of patients receiving 500 mg. These
effects were rapidly occurring in most patients (ie, within
3 weeks in 75% of responding patients). Partial responses
were detected in 12% and in 9% of patients treated with
gefitinib 250 mg and 500 mg respectively. Symptoms
improved in 96% of patients with partial responses. One-
year overall survival was 25%. Also in this study, the
higher dose of gefitinib was associated with worse side
effects, such as acnelike skin rash and diarrhea. On the
basis of these clinical trials, gefitinib has been licensed
for platinum and docetaxel chemorefractory advanced
NSCLC patients as third-line treatment in 10 countries,
including Japan, Australia, and the United States [23].
Therefore, gefitinib represents the first approved anti-
EGFR-targeting drug. Single-agent gefitinib antitumor
activity has also been confirmed by a large, international,
extended access program that has been conducted with
gefitinib 250 mg in advanced NSCLC patients who pro-
gressed after standard chemotherapy and/or radiation
therapy [24,25]. In these series, objective responses have
been observed in 10 to 15% of patients. Moreover, gefi-
tinib clinical activity has been reported in NSCLC el-
derly and/or poor performance status patients as well
[26•,27–29]. Gefitinib monotherapy has also shown an-
ticancer activity against brain metastasis in advanced
NSCLC patients [30•,31•]. Emerging clinical data sup-
port the hypothesis that gefitinib may be significantly
more active in certain NSCLC histotypes such as in ad-
enocarcinomas and in bronchioloalveolar carcinomas and
in women with no smoking history [32•–34•]. The role
of gefitinib in combination with chemotherapy has also
been assessed in advanced NSCLC. A pilot study has
shown that treatment with gefitinib (250 mg or 500 mg
daily dose) in combination with carboplatin–paclitaxel
appeared feasible and well tolerated in previously un-
treated patients with advanced stage IIIB to IV NSCLC
[35]. Pharmacokinetic data demonstrated that coadmin-
istration of gefitinib does not affect the clearance of ei-
ther carboplatin or paclitaxel. Of 24 patients, five had
partial responses (median duration of response, 5
months) and 11 patients obtained disease stabilization.
The median survival for the 24 patients was 8 months.
One-year and 2-year survival rates were 39% and 22%
respectively. The combination of another platinum-
based chemotherapy regimen (cisplatin–gemcitabine)
with oral gefitinib (250-mg or 500-mg daily dose) was
evaluated in 18 advanced NSCLC patients as first-line
treatment (Giaccone et al., Abstract presented at the
AACR-NCI-EORTC International Conference in Mo-
lecular Targets and Cancer Therapeutics, 2001). The
combination was tolerable, with no increase in chemo-
therapy-related toxicity and no interference with the
pharmacokinetics of these drugs. The combination of
gefitinib with docetaxel as second-line treatment is also
under evaluation in advanced NSCLC patients [36,37].
Preliminary results of these studies suggest that both
250- and 500-mg daily doses can be combined with stan-
dard-dose docetaxel (75 mg/m2 every 3 weeks). Two
large (1093 and 1037 patients in each trial respectively),
randomized, multicenter, double-blind, three-arm, pla-
cebo-controlled phase 3 trials of gefitinib (250 mg or 500
mg daily) in combination with cytotoxic agents (cisplat-
in–gemcitabine, Iressa Non-Small-Cell-Lung Cancer
Trial Assessing Combination Treatment [INTACT 1]
trial, or carboplatin–paclitaxel INTACT 2 trial) as first-
line treatment in stages IIIB to IV NSCLC patients were
conducted [38•,39•]. No patient selection based on
EGFR expression in cancer cells was done. No differ-
ence in overall survival, as the primary end point of these
two parallel studies, has been reported. Different expla-
nations for the lack of efficacy of gefitinib plus standard
doublet cytotoxic therapy have been proposed [40,41••].
Chemotherapy and gefitinib could target the same can-
cer cell population and, therefore, response to chemo-
therapy masks the response to the EGFR inhibitor. Che-
motherapy may directly or indirectly affect EGFR
function and/or expression, and thus may reduce or ab-
rogate the antitumor activity of gefitinib. It seems more
conceivable that because of the high molecular and
clonal heterogeneity of NSCLC cells, only a subset of
EGFR-positive NSCLC patients have tumors that are
significantly dependent on the EGFR pathway and who,
therefore, could obtain a clinical benefit by an anti-
EGFR drug [41••]. Interstitial lung disease (ILD) was
first reported in Japanese advanced NSCLC patients re-
ceiving gefitinib and in those who were pretreated with
chemotherapy and/or radiotherapy [42•]. ILD has been
observed in 291 of 17,500 Japanese patients (1.7%)
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treated with gefitinib [42•]. However, ILD has been ob-
served in only 0.3% of 56,000 NSCLC patients who re-
ceived gefitinib in the United States, Europe, and Aus-
tralia as part of an expanded access program [43•]. No
differences in any type of pulmonary adverse events
have been observed in the double-blind, placebo-
controlled, randomized INTACT 1 and 2 trials (0.9% in
the placebo group compared with 1.1% in the 250-
mg/day and the 500-mg/day gefitinib groups) [38•,39•].
Notably, ILD has been observed in NSCLC patients
receiving standard cytotoxic treatments (1 to 5% inci-
dence with chemotherapy or with radiotherapy) [43•]. A
series of phase 3 trials is currently evaluating the role of
gefitinib as adjuvant treatment in radically resected
NSCLC patients, the possibility of using gefitinib as
maintenance therapy after first-line chemotherapy in ad-
vanced NSCLC patients, and the antitumor activity of
gefitinib compared with docetaxel in the second-line
treatment of advanced disease.
Erlotinib
Erlotinib is a low-molecular weight, orally bioavailable,
quinazoline derivative that selectively and reversibly in-
hibits the tyrosine kinase activity of EGFR [44]. Phase 1
studies in patients with advanced solid tumors have
shown a tolerability profile similar to gefitinib. Major
toxicities were acnelike skin rash and diarrhea, which
was the dose-limiting toxicity at 200 mg daily. The rec-
ommended dose for continuous treatment was 150
mg/day [44]. Erlotinib is currently in phase 2 to phase 3
development in advanced NSCLC. Preliminary evi-
dence of antitumor activity of erlotinib in patients with
advanced NSCLC who failed a platinum-based therapy
was recently reported [45]. In this phase 2 study, a com-
plete response was observed in 1 of 57 patients, and
partial responses were obtained in six patients. Stable
disease was detected in an additional 17 patients. The
median survival for these patients was 259 days, with a
1-year survival of 48%. A retrospective analysis of acne-
like rash occurrence in this phase 2 study has suggested
that rash severity (grade 2 or more) compared with no
skin lesions is predictive of increased survival (no rash,
1.5 months median survival; grade 1 toxicity, 8.5 months
median survival; grade 2 to 3 toxicity, 19.6 months me-
dian survival) [46••]. Based on these observations and on
the hypothesis that skin rash may be a surrogate for clini-
cal activity, a trial has recently been initiated in chemo-
therapy refractory advanced NSCLC patients to evaluate
the feasibility of erlotinib dose escalation to induce tol-
erable rash without other toxicities. Interestingly, no cor-
relation between the degree of skin toxicity and outcome
has been observed so far with gefitinib clinical trials. A
series of phase 2 and phase 3 studies of erlotinib as a
single agent or in combination with various chemo-
therapy regimens is ongoing in NSCLC [47]. In this re-
spect, erlotinib treatment as a single agent is also under
evaluation in the second- or third-line treatment of ad-
vanced NSCLC patients in two randomized phase 3
clinical trials in comparison with docetaxel or with best
supportive care respectively. Similar to the INTACT tri-
als, two large (approximately 1000 patients in each
study), multicenter, randomized, phase III studies of
first-line carboplatin–paclitaxel or cisplatin–gemcitabine
with erlotinib in stage IIIB to IV NSCLC patients have
been performed (47). On October 1, 2003, a press release
from the industries (Genentech, San Francisco, CA;
Roche, Basel, Switzerland; and OSI Pharmaceuticals,
Boulder, CO) that are producing erlotinib stated that
both studies, similar to the INTACT studies with gefi-
tinib, failed to show any difference in overall survival
between the standard and the erlotinib treatment.
Cetuximab
Cetuximab is a chimeric human–mouse IgG1 anti-
EGFR-blocking MAb. It was the first anti-EGFR-
targeted agent to start clinical evaluation in cancer pa-
tients [48]. In the phase 1 studies the most frequent
cetuximab-related adverse events were skin toxicities,
fever and chills, asthenia, transient transaminase eleva-
tions, and nausea [49]. Skin toxicities were reversible
flushing, acnelike rashes, and folliculitis. The maximum
tolerated dose was not reached. Cetuximab had nonlin-
ear pharmacokinetics. Based on the doses for complete
saturation of antibody clearance, the recommended load-
ing dose and the subsequent weekly maintenance doses
for phase 2 studies were 400 mg/m2 and 250 mg/m2 re-
spectively. The combination of cetuximab with various
two-drug chemotherapy regimens has been evaluated as
first-line treatment in EGFR-positive advanced NSCLC
patients. In a phase 1/2 trial of cetuximab plus carboplat-
in–gemcitabine chemotherapy, 10 partial responses
(28.6%) and 11 stable diseases (60%) in 35 patients were
observed [50]. The median time to progression and the
median overall survival were 165 days and 310 days re-
spectively. The combination of carboplatin–paclitaxel
plus cetuximab was evaluated in 31 patients as first-line
treatment in EGFR-positive advanced NSCLC [51].
Partial responses were observed in nine patients (29%)
and disease stabilization was obtained in the other 11
patients (35.5%), with a median time to progression of
4.5 months and a median overall survival of 15.7 months.
A phase 2 trial of cetuximab in combination with doce-
taxel as second-line treatment in chemotherapy
refractory/resistant EGFR-positive advanced NSCLC
has recently been reported [52]. One complete response
and 11 partial responses (overall response rate, 22.2%)
were observed in the 54 treated patients. The other 18
patients (33.3%) had stable disease. The median overall
survival was 7.5 months. The initial results of a random-
ized, phase 2 study (LUCAS, or Lung Cancer Cetuximab
Combination Study) comparing as first-line therapy cis-
platin–vinorelbine with the same combination plus ce-
tuximab in EGFR-positive stage IIIB to IV NSCLC pa-
tients have been presented. A higher response rate with
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no increase in chemotherapy toxicity was observed in the
chemotherapy plus cetuximab group compared with the
chemotherapy-alone group: one complete response and
15 partial responses out of 30 treated patients (53.3%
response rate) versus 10 partial responses in 31 treated
patients (32.2% response rate) [54••]. However, com-
plete data from this study and phase 3 trials are necessary
to define whether cetuximab significantly improves the
activity and the efficacy of standard chemotherapy in
NSCLC.
Conclusion
Both anti-EGFR MAbs and small-molecule TKIs have
shown an excellent toxicity profile with mild and revers-
ible side effects in NSCLC patients. However, a series of
clinically important issues on the use of EGFR-targeted
therapies in NSCLC is emerging [54••]. First, the im-
portance of the measurement of the levels of expression
of EGFR within the tumor to select cancer patients for
treatment with these drugs is not yet clear. Although
EGFR expression is found in most NSCLCs, responses
are observed only in a subgroup of patients. There is no
evidence of a relation between EGFR overexpression
and likelihood to respond to anti-EGFR drugs. More-
over, it seems that adenocarcinomas and bronchioloal-
veolar carcinomas are more sensitive than squamous cell
carcinomas. Furthermore, it could be necessary for the
response to EGFR inhibitors the expression of the other
three EGFR-related receptors and of the EGFR ligands
such as transforming growth factor- and amphiregulin.
Finally, the intracellular signal transduction pathways
that act downstream to EGFR could influence the re-
sponse to anti-EGFR agents. In this respect, cancer cells
may escape from growth inhibition by using alternative
growth pathways or by constitutive activation of down-
stream signaling effectors [54••]. In summary, the imple-
mentation of translational, research-oriented clinical tri-
als with EGFR inhibitors in NSCLC is needed to
establish fully their role in NSCLC management. The
major aims of these studies should be the identification
of clinically relevant molecular markers of potential sen-
sitivity or resistance to therapy, and the identification of
pharmacologic and mechanistic interactions of anti-
EGFR agents and chemotherapy or radiotherapy for the
more appropriate integration of these drugs with conven-
tional treatment.
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